Document Type : Review Article

Authors

Department of Anesthesiology and Reanimation, Faculty of Medicine, Airlangga University – Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

10.48309/jmpcr.2024.451804.1186

Abstract

Chronic pain is a serious issue among cancer patients, with nearly half of all cancer patients experiencing it. Approximately 5-20% of these patients report suffering from severe pain that impacts their quality of life, and unresolved chronic pain may even affect the survival of cancer patients. Breakthrough cancer pains (BTcP) are a major concern for many people around 60% of cancer patients who experience pain. Despite efforts to improve pain management, many countries still report errors in assessing and treating this type of pain. Opinions about prescribing opioids for cancer pain have changed over time. Tetrahydrobiopterin (BH4) regulation may play a part in cancer pain mechanisms. A brief summary of the effectiveness of opioid treatment is provided in this study in chronic cancer pain patients who experience BTcP, assessed by biomarkers in BH4 pathway.

Graphical Abstract

The effectiveness of opioid treatment in patients with chronic cancer pain experiencing breakthrough cancer pain (BTcP): Biomarker evaluation in the tetrahydrobiopterin pathway

Keywords

Main Subjects

[1] F. Mestdagh, A. Steyaert, P. Lavand’homme, Cancer pain management: A narrative review of current concepts, strategies, and techniques, Current Oncology, 2023, 30, 6838–6858. [Crossref], [Google Scholar], [Publisher]‎
[2] R. Snijders, L. Brom, M. Theunissen, M. van den Beuken-van Everdingen, Update on prevalence of pain in patients with cancer 2022: A systematic literature review and meta-analysis, Cancers (Basel), 2023, 15, 591. [Crossref], [Google Scholar], [Publisher]‎
[3] F. Marinangeli, A. Saetta, A. Lugini, Current management of cancer pain in Italy: Expert opinion paper, Open Medicine, 2021, 17, 34–45. [Crossref], [Google Scholar], [Publisher]‎
[4] S. Gonella, R. Sperlinga, V. Sciannameo, V. Dimonte, S. Campagna, Characteristics of breakthrough pain and its impact on quality of life in terminally Ill cancer patients, Integrative Cancer Therapies, 2019, 18. 153473541985909. [Crossref], [Google Scholar], [Publisher]‎
[5] A. Gatti, M. Gentili, M. Baciarello, M. Lazzari, R. Marzi, E. Palombo, A.F. Sabato, G. Fanelli, Breakthrough pain in patients with controlled or uncontrolled pain: An observational study, Pain Research and Management, 2014, 19, 168–171. [Crossref], [Google Scholar], [Publisher]‎
[6] C. Batistaki, M. Graczyk, M. Janecki, A.A. Lewandowska, R. Moutinho, K. Vagdatli, Relationship between breakthrough cancer pain, background cancer pain and analgesic treatment– case series and review of the literature, Drugs Context, 2022, 11, 1–10. [Crossref], [Google Scholar], [Publisher]‎
[7] S. Mercadante, Treating breakthrough pain in oncology, Expert Review of Anticancer Therapy, 2018, 18, 445–449. [Crossref], [Google Scholar], [Publisher]‎
[8] S. Mercadante, A. Caraceni, A. Cuomo, M. Mammucari, P. Marchetti, R.D. Mediati, S. Natoli, G. Tonini, A longitudinal study of breakthrough cancer pain: An extension of IOPS-MS study, Journal of Clinical Medicine, 2021, 10, 2273. [Crossref], [Google Scholar], [Publisher]‎
[9] M. Cascella, A. Crispo, G. Esposito, C. Forte, S. Coluccia, G. Porciello, A. Amore, S. Bimonte, S. Mercadante, A. Caraceni, M. Mammucari, P. Marchetti, R. Mediati, S. Natoli, G. Tonini, A. Cuomo, Multidimensional statistical technique for interpreting the spontaneous breakthrough cancer pain phenomenon. A secondary analysis from the IOPS-MS study, Cancers (Basel), 2021, 13, 4018. [Crossref], [Google Scholar], [Publisher]‎
[10] S. Mercadante, Once again... breakthrough cancer pain: an updated overview, Journal of Anesthesia, Analgesia and Critical Care, 2023, 3, 23. [Crossref], [Google Scholar], [Publisher]‎
[11] M.I. Bennett, E. Eisenberg, S.H. Ahmedzai, A. Bhaskar, T. O’Brien, S. Mercadante, N. Krčevski Škvarč, K. Vissers, S. Wirz, C. Wells, B. Morlion, Standards for the management of cancer‐related pain across Europe—A position paper from the EFIC Task Force on Cancer Pain, European Journal of Pain, 2019, 23, 660–668. [Crossref], [Google Scholar], [Publisher]‎
[12] G. Brozović, N. Lesar, D. Janev, T. Bošnjak, B. Muhaxhiri, Karcinomska bol i terapija,  Acta Clinica Croatica2022, 61, 103-108. [Crossref], [Google Scholar], [Publisher]‎
[13] B.M. Scarborough, C.B. Smith, Optimal pain management for patients with cancer in the modern era, CA: A Cancer Journal for Clinicians, 2018, 68, 182–196. [Crossref], [Google Scholar], [Publisher]‎
[14] R. Haroun, J.N. Wood, S. Sikandar, Mechanisms of cancer pain, Frontiers in Pain Research, 2023, 3, 1030899. [Crossref], [Google Scholar], [Publisher]‎
[15] Z. Hussain, The Holistic approach to cancer pain management, Ulster Medical Journal, 2022, 91, 45–49. [Google Scholar], [Publisher]‎
[16] S. Dalal, E. Bruera, Management of pain in the cancer patient, Frontiers in Pain Research, 2022, 3. [Crossref], [Google Scholar], [Publisher]‎
[17] E. Sir, G.D. Batur Sir, Evaluating treatment modalities in chronic pain treatment by the multi-criteria decision making procedure, BMC Medical Informatics and Decision Making, 2019, 19, 191. [Crossref], [Google Scholar], [Publisher]‎
[18] M. Raad, W.O.C. López, A. Sharafshah, M. Assefi, K.-U. Lewandrowski, personalized medicine in cancer pain management, Journal of Personalized Medicine, 2023, 13, 1201. [Crossref], [Google Scholar], [Publisher]‎
[19] S. Mackey, H.T. Greely, K.T. Martucci, Neuroimaging-based pain biomarkers: Definitions, clinical and research applications, and evaluation frameworks to achieve personalized pain medicine, Pain Reports, 2019, 4,  762. [Crossref], [Google Scholar], [Publisher]‎
[20] A.M. Ningrum, P.S. Airlangga, W.I. Maskoep, H.S. Putri, Relationship of quinolinic acid and serotonin with depression and pain degree in cancer pain patients: A cross-sectional study, Bali Medical Journal, 2023, 12, 2681–2684. [Crossref], [Google Scholar], [Publisher]‎
 [21] I. Tracey, C.J. Woolf, N.A. Andrews, Composite pain biomarker signatures for objective assessment and effective treatment, Neuron, 2019, 101, 783–800. [Crossref], [Google Scholar], [Publisher]‎
[22] A.N.M. Ansori, M.H. Widyananda, Y. Antonius, A.A.A. Murtadlo, V.D. Kharisma, P.A. Wiradana, S. Sahadewa, F.D. Durry, N. Maksimiuk, M. Rebezov, R. Zainul, A review of cancer-related hypercalcemia: Pathophysiology, current treatments, and future directions, Journal of Medicinal and Pharmaceutical Chemistry Research, 2024, 6, 944–952. [Crossref], [Pdf], [Publisher]‎
[23] J. Gunn, M.M. Hill, B.M. Cotten, T.R. Deer, An analysis of biomarkers in patients with chronic pain, Pain Physician, 2020, 23, 41–49. [Crossref], [Google Scholar], [Publisher]‎
[24] S.J.F. Cronin, S. Rao, M.A. Tejada, B.L. Turnes, S. Licht-Mayer, T. Omura, C. Brenneis, E. Jacobs, L. Barrett, A. Latremoliere, N. Andrews, K.M. Channon, A. Latini, A.C. Arvanites, L.S. Davidow, M. Costigan, L.L. Rubin, J.M. Penninger, C.J. Woolf, Phenotypic drug screen uncovers the metabolic GCH1/BH4 pathway as key regulator of EGFR/KRAS-mediated neuropathic pain and lung cancer, Science Translational Medicine, 2022, 14, 1531. [Crossref], [Google Scholar], [Publisher]‎
[25] A. Staats Pires, V.X. Tan, B. Heng, G.J. Guillemin, A. Latini, Kynurenine and tetrahydrobiopterin pathways crosstalk in pain hypersensitivity, Front Neurosci, 2020, 14, 518534. [Crossref], [Google Scholar], [Publisher]‎
[26] E. Mutiawati, S. Syahrul, N. Musadir, Brain alteration in chronic pain and the relationship with pain score, Bali Medical Journal, 2020, 9, 461–465. [Crossref], [Google Scholar], [Publisher]‎